Boston Scientific Corp (BSX) Buy, Sell or Hold

Boston Scientific Corp (BSX)

45.37

+0.32 (0.71%)

as of Oct 20, 2026, 5:33:00 pm Market Open.

102 watching

PAST TOP PICK

(A Top Pick Dec 01/20, Up 33%) He would buy it again. They had a decade of no-growth. In the last 3-5 years they introduced successful products that got their revenue going again. A lot of their procedures are not necessary today but will be over the next few months. The volumes are coming back. It is at the cheaper end of a lot of healthcare stocks.

BUY ON WEAKNESS

It's one of Abbott's biggest competitors. It's in an attractive industry, medical equipment, where companies earn good returns. But BSX's valuation is high, gotten ahead of itself (like the whole sector), so wait for a pullback. BSX had a strong quarter as non-elective surgeries have bounced back, but its PE is rich.

PAST TOP PICK

(A Top Pick Jul 14/20, Up 23%) It had a couple of disappointing news items involving a couple of their products. They are playing catch-up on elective surgeries. It is one he really likes and continues to hold.

TOP PICK

It is a medical device company and people are starting to be able to get in to see their doctor and take care of things. A lot of their revenues are tied to non-deferrable procedures. That is positive for the whole group and they have company-specific catalysts also. (Analysts’ price target is $49.00)

HOLD

Looking at the longer term chart, they had a dip around the time China announced first cases of covid. Underperformed relative to others, like other mid-tech companies. Lots of procedures were delayed in hospitals. Now there will be catch up for this. At these levels, there is still some room to run. Could go to $48 range.

BUY

Hit a 52-week high today. This sector (medical devices) has reported very strong reports, such as Intuitive Surgical.

DON'T BUY

Liked it better in the past than today. If there were a recession, they'd need more capital. Remains a very fine company as to products. Good management that will learn from the past. Volumes in medical devices are not recovering as he expected. He owns Abbott Labs instead, a diversified player with a very strong balance sheet. You could also look at the dental space.

HOLD

Cardiovascular-related devices, and they're doing very well. Raised equity, and pulled a device from market due to potential safety issues. Took a bit of a hit on earnings. Likes it, but he's watching closely as it becomes more concentrated.

TOP PICK

One of the largest medical device manufacturers. New management has cleaned things up. Stock hit by a heart valve recall. Substantial upside. No dividend. (Analysts’ price target is $42.96)

BUY

It has been impacted. From 2013 to 2019 they could do no wrong, then there were a few hiccups. They discontinued one of their hard-valve products that will impact their growth over the next 3-4 years. If you think management can continue to execute and hit a couple of home runs, then stick with it. He would consider it a buy at these levels.

BUY

BSX vs. BDX Owns Boston Scientific instead of BDX. BSX has a strong history of execution. One-time events threw off that execution. Hospital procedures are coming back, which will benefit the entire industry. Well known for innovation.

BUY

Allan Tong’s Discover Picks It trades at a 32x PE, but pays no dividend. Despite the spring lockdown, BSX offers revenue growth YOY of 9.28% though the one-year total return is -5.42%. It beat EPS in three of its last four earnings periods, and the market expects its EPS to leap from 8 cents in Q2 to 24 cents in Q3 (to reported on Oct. 21). Read BDX, BSX, ISRG and Stryker Stock: Top 4 Medical Supply Stocks for our full analysis.

BUY

BSX vs. CCI One of his biggest holdings and fully believes in it. They suffered because their medical devices are non-essential, but they will recover nicely in time. Crown Castle is very different, a real estate play for cell phone towers, which will see strong growth, but the PE is very high given this expected growth. There's little risk though. You can buy both stocks.

TOP PICK

One of the fastest-growiong medical device companies. This has been unfairly beaten up during the pandemic with a delay in elective surgeries. When those operations return, BSX should do well. (Analysts’ price target is $42.96)

COMMENT

Had an exceptional 10 years. Sold off heavily with the coronavirus. High growth. Challenge is you couldn't buy it if you were a value investor. Supply of components will be an issue, as for all its peers.

Showing 31 to 45 of 74 entries

Most Recent Experts

Keith Richards

ValueTrend Wealth Management

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Bruce Campbell (2)

Stone Castle Investment Management Inc.

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Boston Scientific Corp (BSX)